Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could antibody infusions help prevent HIV? new trial begins

NCT ID NCT06812494

Ongoing Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether a combination of three lab-made antibodies is safe and tolerable in 200 healthy adults without HIV. Participants receive one or more IV infusions of the antibodies and are followed for 18 months. The goal is to see if this approach could eventually be used to prevent or control HIV infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
three lab-made antibodies (VRC07-523LS, PGT121.414.LS, PGDM1400LS) given by IV infusion
What this could lead to
If successful, this could point toward a new way to prevent or control HIV using infusions of antibodies instead of daily pills.
What could go wrong
This is an early phase 2 trial focused on safety, so it is not yet testing whether the antibodies actually prevent HIV. The antibodies may not work as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

  • ACSA CRS

    Iquitos, Maynas, 1, Peru

  • Alabama CRA (Site #31788)

    Birmingham, Alabama, 35222, United States

  • BIDMC VCRS (Site ID# 32077)

    Boston, Massachusetts, 02215, United States

  • Bridge HIV, San Francisco Department of Public Health

    San Francisco, California, 94102, United States

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

    Boston, Massachusetts, 02115-6110, United States

  • CITBM CRS (Site ID 31970)

    Callao, Provincia Constitucional del Callao, 15081, Peru

  • Chapel Hill CRS (Site #3201)

    Chapel Hill, North Carolina, 27599, United States

  • Chatsworth CRS

    Chatsworth, KwaZulu-Natal, 4030, South Africa

  • Columbia P&S CRS

    New York, New York, 10032, United States

  • Fenway Health

    Boston, Massachusetts, 02215-4302, United States

  • Groote Schuur HIV CRS

    Cape Town, Western Cape, 7925, South Africa

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    Rio de Janeiro, Rio de Janeiro, 21040-360, Brazil

  • Penn Prevention CRS

    Philadelphia, Pennsylvania, 19104, United States

  • Perinatal HIV Research Unit (PHRU)

    Johannesburg, Gaunteng, 1862, South Africa

  • San Miguel CRS (Site #11302)

    Lima, 32-15088, Peru

  • Seattle Vaccine and Prevention CRS (Site ID# 30331)

    Seattle, Washington, 98104, United States

  • Setshaba Research Centre

    Soshanguve-H, Soshanguve, 0152, South Africa

  • The Hope Clinic of the Emory Vaccine Research Center; Emory University

    Decatur, Georgia, 30030, United States

  • University of Pittsburgh CRS (Site 1001)

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Rochester Vaccines to Prevent HIV Infection CRS (Site ID 31467)

    Rochester, New York, 14642, United States

  • Vanderbilt Vaccine (VV) CRS

    Nashville, Tennessee, 37232, United States

  • Via Libre (Site ID 31909)

    Lima, Lima Province, 15001, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.